- Home
- WRN vs CLLS Comparison
WRN vs CLLS Comparison
Compare WRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.67
HOLD
Current Price
$4.14
Company Overview
Basic Information| Metric | WRN | CLLS |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 299.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | WRN | CLLS |
|---|---|---|
| Price | $2.67 | $4.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.13 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.0M | 136.1K |
| Earning Date | 03-24-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $0.90 | $1.10 |
| 52 Week High | $2.71 | $5.48 |
Technical Indicators
Market Signals| Indicator | WRN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 69.90 | 45.67 |
| Support Level | $2.51 | $4.47 |
| Resistance Level | $2.71 | $5.45 |
| Average True Range (ATR) | 0.11 | 0.30 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 93.75 | 17.53 |
Price Performance
Historical Comparison WRN
CLLS
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.